CoChat

c‐Jun N‐terminal kinase signaling in the pathogenesis of nonalcoholic fatty liver disease: Multiple roles in multiple steps†‡

Open access
Kodama, Yuzo, Brenner, David A. · 2009 · Hepatology
Cited by 73

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

The c-Jun N-terminal kinase (JNK) is a member of an evolutionarily conserved subfamily of mitogen-activated protein kinases (MAPKs). JNK regulates various cellular responses such as differentiation, proliferation, migration, immune reaction, and cell death in response to a diverse range of extracellular stimuli.1 Gene deletion and pharmacological interventions have revealed that JNK signaling is required for acute hepatocellular injury, liver regeneration, and carcinogenesis.2-7 In addition, JNK plays a central role in obesity and insulin resistance.8 Therefore, JNK has attracted attention as a key regulator in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). AP-1, activator protein-1; ASO, antisense oligonucleotide; ER, endoplasmic reticulum; FFAs, free fatty acids; IRS, insulin receptor substrate; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NF-κB, nuclear factor-κB; TNF-α, tumor necrosis factor-α. NAFLD is a spectrum of liver disorders ranging from simple steatosis to nonalcoholic steatohepatitis (NASH) and liver fibrosis, and is commonly associated with clinical features of the metabolic syndrome such as obesity, type II diabetes, and dyslipidemia. A "two-hit" model has been proposed for the development of NALFD.9 The "first hit" is the initial hepatic lipid accumulation, but a "second hit" is required for liver injury and inflammation. JNK has been implicated to play a role in both of these "hits". First, increased JNK activity can promote the insulin resistance that underlies the development of metabolic syndrome, including hepatic steatosis. Second, hepatic oxidative stress, which is a major candidate for the "second hit", could cause cellular injury and trigger inflammation through JNK activation. Thus, JNK might play a pivotal role in each step of the pathogenesis of NAFLD. Indeed, recent studies have demonstrated that JNK is activated in the livers of patients with NASH, and that genetic deletion of JNK isoforms attenuates hepatic steatosis in experimental animal models.10-12 Given the potential for JNK inhibition as a possible therapy for insulin resistance/diabetes,13 an in-depth understanding of the role of JNK in the pathogenesis of NAFLD is of critical importance. However, because of the ubiquitous expression of two JNK isoforms (JNK1 and JNK2) and their functional redundancy, compensation, or individuality, it has been difficult to interpret the distinctive roles for JNK isoforms in liver disease. In this issue of HEPATOLOGY, by using the combination of gene knockout and knockdown techniques in mice, Singh and coworkers14 elegantly illustrated the differential contributions of JNK1 and JNK2 in multiple steps of the pathogenesis of NAFLD, and expanded the possibilities of selective inhibition of a JNK isoform as a future therapy for NAFLD. Obesity and insulin resistance are the two major risk factors for NAFLD. In short, systemic insulin resistance, especially at the level of adipocytes, enhances the flux of free fatty acids (FFAs) to the liver. In addition, increased de novo lipogenesis due to hyperinsulinemia induces hepatic steatosis, a "first hit" of NAFLD. This is the differential or selective insulin resistance. JNK plays a central role in both systemic and hepatic insulin resistance through serine phosphorylation of the insulin receptor substrate (IRS)-1 and IRS-2, leading to down-modulation of tyrosine phosphorylation of these molecules, which is required for normal insulin signaling.8, 15 In fact, JNK activation induced by various stimuli such as obesity-induced inflammation, FFAs, oxidative stress, or endoplasmic reticulum (ER) stress, mediates insulin resistance and subsequent hepatic steatosis. Singh and coworkers investigated the distinct roles for JNK1 and JNK2 in developing or established insulin resistance and hepatic steatosis by using genetic knockout or antisense oligonucleotide (ASO) knockdown techniques in mice fed a high-fat diet, respectively. In addition to reproducing the previously reported decreased incidence of insulin resistance in jnk1−/− but not in jnk2−/− mice, they found that ASO knockdown of either JNK1 or JNK2 is able to reverse the established insulin resistance, mimicking a gene targeting therapy. Given that ASOs are preferentially delivered to the liver, JNK ablation in the liver may improve not only hepatic but also systemic insulin sensitivity. Furthermore, they demonstrated that ablation of JNK1 but not JNK2 improved hepatic steatosis. The differential effect of JNK2 knockdown, which is effective on insulin resistance but not on hepatic steatosis, highlights that hepatic steatosis is more than a mere consequence of insulin resistance. JNK1 might have a direct effect on hepatic lipogenesis that is independent of insulin resistance. A previous article supports these results, in that ASO treatment against JNK1 reduces hepatocyte lipid product

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.22710

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 73

Metadata

Authors
Kodama, Y., & Brenner, D. A.
Venue
Hepatology
Published
2009-01
Volume
49
Issue
1
Pages
6-8
ISSN
0270-9139 (ISSN-L)
OpenAlex
W2027205411
Cited by
73
References
8
FWCI
2.85
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.